Research programe: endogenous retrovirus cancer vaccines - Evaxion Biotech
Alternative Names: ERV cancer vaccinesLatest Information Update: 30 May 2025
At a glance
- Originator Evaxion Biotech
- Class Antineoplastics; Cancer vaccines; Immunotherapies
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Research Cancer
Most Recent Events
- 02 Apr 2025 Early research in Cancer in Denmark (Parenteral) prior to April 2025
- 01 Apr 2025 Evaxion Biotech plans a identification of lead candidate in Cancer in second half of 2025
- 13 Feb 2025 Evaxion Biotech has patents pending for 'Personalized cancer therapy targeting normally non-expressed sequences' in USA